This post was originally published on this site Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and Parkinson’s diseases, according to results from the ongoing Phase 3 HARMONY study. Evaluation by an independent data monitoring committee recommended an early stop to this trial based on the treatment’s “robust”…
Conditions
Conditions
These Essential Supplies Make Caregiving a Little Easier
This post was originally published on this site The hardest job becomes easier when the right supplies are on hand. This is especially true with caregiving. Every day is a learning experience. We learn what is essential for the care and the service of the person we are caring for. The following tools and materials…
Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
This post was originally published on this site Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst (pomalidomide) and low-dose dexamethasone, results of a Phase 2 clinical trial in a first patient group suggest. An overall response “was achieved by 32·1% of…
Long-term Extension Study of Anavex 2-73, Potential Treatment of Alzheimer’s Dementia, Opens
This post was originally published on this site Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company’s 48-week ANAVEX2-73-AD-004 study underway in…
Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS…
FDA Grants Breakthrough Therapy Status to Ofev for Sarcoidosis, Other ILDs
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over currently available…
New MMRF Patient Registry Aims to Help Develop Personalized Treatments for Multiple Myeloma
This post was originally published on this site Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with multiple myeloma to securely submit their health data to MMRF CureCloud, the foundation’s data repository. This is the first data repository to gather people’s longitudinal…
Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer
This post was originally published on this site A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical trial. The LPC-004 Phase 2b trial (NCT03348527) is ongoing at specialist urology clinics in Canada, Lithuania, and…
Phio Partners with German Research Center to Develop New Generation of Cancer Immunotherapies
This post was originally published on this site Phio Pharmaceuticals and researchers with Helmholtz Zentrum München — the German Research Center for Environmental Health (HMGU) — are working together to develop new approaches to boost the immune system in fighting cancer. The collaboration aims to use Phio’s proprietary self-delivering RNAi (sd-rxRNA) technology to inhibit checkpoint molecules in…
Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show
This post was originally published on this site IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials show. The data, confirming that both trials achieved their primary endpoints, were presented at the 22nd Annual…
Fujifilm SonoSite, AI2 Incubator Work on Using AI to Improve Ultrasound Imaging
This post was originally published on this site Fujifilm SonoSite is collaborating with the Allen Institute of Artificial Intelligence (AI2) Incubator to use artificial intelligence to improve the accuracy of ultrasound images, the standard way to detect ovarian cancer. A developer of bedside and point-of-care ultrasound, Fujifilm SonoSite paired with the AI2 Incubator to use…
Oral Anticoagulant Dabigatran Prevented Memory Loss in Mouse Model of Alzheimer’s, Study Shows
This post was originally published on this site Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in a mouse model of Alzheimer’s disease. The study with that finding, “Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis…